Trends in door-to-balloon time and mortality in patients with ST-elevation myocardial infarction un- dergoing primary percutaneous coronary intervention. Arch Intern Med. 2010;170:1842 9. 637. Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010;376:1312 9. 638. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9 19. 639. Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vora- paxar in acute coronary syndromes. N Engl J Med. 2012;366:20 33. 640. Bekkers SCAM, Yazdani SK, Virmani R, et al. Microvascular obstruc- tion: underlying pathophysiology and clinical diagnosis. J Am Coll Car- diol. 2010;55:1649 60. 641. Timmers L, Henriques JPS, de Kleijn DPV, et al. Exenatide reduces in- farct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol. 2009;53:501 10. 642. Wu KC. Fighting the fire of myocardial reperfusion injury: how to de- fine success? J Am Coll Cardiol. 2009;53:730 1. 643. Deleted in press. 644. Prasad A, Stone GW, Holmes DR, et al. Reperfusion injury, microvas- cular dysfunction, and cardioprotection: the dark side of reperfusion. Circulation. 2009;120:2105 12. 645. Patti G, Cannon CP, Murphy SA, et al. Clinical benefit of statin pre- treatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. Cir- culation. 2011;123:1622 32. 646. Dorian P, Hohnloser SH, Thorpe KE, et al. Mechanisms underlying the lack of effect of implantable cardioverter-defibrillator therapy on mortal- ity in high-risk patients with recent myocardial infarction: insights from the Defibrillation in Acute Myocardial Infarction Trial (DINAMIT). Cir- culation. 2010;122:2645 52. 647. Terzic A, Nelson TJ. Regenerative medicine advancing health care 2020. 